Literature DB >> 24874469

Lower apparent diffusion coefficients indicate distinct prognosis in low-grade and high-grade glioma.

Yong Cui1, Li Ma, Xuzhu Chen, Zhe Zhang, Haihui Jiang, Song Lin.   

Abstract

Tumor grade and molecular variants influence the survival of patients with glioma. The apparent diffusion coefficient (ADC) map is a non-invasive tool for evaluating the outcomes and response to therapy in glioma. In this study, we investigated the correlation between the tumor grade and prognostic biomarkers with the ADC in glioma patients. Eighty-two patients with supratentorial glioma were identified via analysis of surgical specimens and neuroradiological data. Using the World Health Organization grade, histological subtype, and molecular variants (1p/19q codeletion, isocitrate dehydrogenase 1/2 mutation, Ki-67 index, O6-methylguanine DNA methyltransferase, P53, and vascular endothelial growth factor immunoactivity) as prognostic biomarkers, we performed receiver operating characteristic analysis and multiple linear regression to assess the association between the magnetic resonance diffusion parameter and mean ADC and the prognostic factors of glioma pathology. Univariate analysis and multiple linear regression revealed inverse correlations between the ADC values and the tumor grade, oligodendrocytoma histology, and 1p/19q codeletion. A threshold mean ADC value could predict the 1p/19q chromosomal status in WHO II gliomas with 72 % sensitivity and 88 % specificity (area under the curve 0.82, 95 % confidence interval 0.68-0.97) and could distinguish low-grade glioma with low-risk factors from the high-risk group (P < 0.01). The mean ADC value could be used as a non-invasive tool to evaluate the prognosis of supratentorial glioma patients. A threshold mean ADC value could be used to predict the 1p/19q codeletion and to identify low-risk low-grade gliomas (LGGs). Lower ADC values are indicative of a favorable prognosis in LGGs.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24874469     DOI: 10.1007/s11060-014-1490-6

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  33 in total

1.  Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas.

Authors:  T Sugahara; Y Korogi; M Kochi; I Ikushima; Y Shigematu; T Hirai; T Okuda; L Liang; Y Ge; Y Komohara; Y Ushio; M Takahashi
Journal:  J Magn Reson Imaging       Date:  1999-01       Impact factor: 4.813

Review 2.  Recent developments in the molecular characterization and treatment of oligodendroglial tumors.

Authors:  Martin van den Bent; Olivier-Louis Chinot; J Gregory Cairncross
Journal:  Neuro Oncol       Date:  2003-04       Impact factor: 12.300

3.  MRI apparent diffusion coefficient reflects histopathologic subtype, axonal disruption, and tumor fraction in diffuse-type grade II gliomas.

Authors:  Inas S Khayal; Scott R Vandenberg; Kenneth J Smith; Colleen P Cloyd; Susan M Chang; Soonmee Cha; Sarah J Nelson; Tracy R McKnight
Journal:  Neuro Oncol       Date:  2011-08-24       Impact factor: 12.300

4.  Malignant supratentorial astrocytoma treated with postoperative radiation therapy: prognostic value of pretreatment quantitative diffusion-weighted MR imaging.

Authors:  Ryuji Murakami; Takeshi Sugahara; Hideo Nakamura; Toshinori Hirai; Mika Kitajima; Yoshiko Hayashida; Yuji Baba; Natsuo Oya; Jun-Ichi Kuratsu; Yasuyuki Yamashita
Journal:  Radiology       Date:  2007-03-13       Impact factor: 11.105

5.  Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma.

Authors:  Daniel A Hamstra; Thomas L Chenevert; Bradford A Moffat; Timothy D Johnson; Charles R Meyer; Suresh K Mukherji; Douglas J Quint; Stephen S Gebarski; Xiaoying Fan; Christina I Tsien; Theodore S Lawrence; Larry Junck; Alnawaz Rehemtulla; Brian D Ross
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-02       Impact factor: 11.205

6.  Multimodal MR imaging (diffusion, perfusion, and spectroscopy): is it possible to distinguish oligodendroglial tumor grade and 1p/19q codeletion in the pretherapeutic diagnosis?

Authors:  S Fellah; D Caudal; A M De Paula; P Dory-Lautrec; D Figarella-Branger; O Chinot; P Metellus; P J Cozzone; S Confort-Gouny; B Ghattas; V Callot; N Girard
Journal:  AJNR Am J Neuroradiol       Date:  2012-12-06       Impact factor: 3.825

7.  Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions.

Authors:  K Hoang-Xuan; L Capelle; M Kujas; S Taillibert; H Duffau; J Lejeune; M Polivka; E Crinière; Y Marie; K Mokhtari; A F Carpentier; F Laigle; J M Simon; P Cornu; P Broët; M Sanson; J Y Delattre
Journal:  J Clin Oncol       Date:  2004-08-01       Impact factor: 44.544

8.  Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome.

Authors:  G Kaloshi; A Benouaich-Amiel; F Diakite; S Taillibert; J Lejeune; F Laigle-Donadey; M-A Renard; W Iraqi; A Idbaih; S Paris; L Capelle; H Duffau; P Cornu; J-M Simon; K Mokhtari; M Polivka; A Omuro; A Carpentier; M Sanson; J-Y Delattre; K Hoang-Xuan
Journal:  Neurology       Date:  2007-05-22       Impact factor: 9.910

9.  A new prognostic scoring scale for patients with primary WHO grade III gliomas based on molecular predictors.

Authors:  Haihui Jiang; Xiaohui Ren; Wei Zhang; Jun Ma; Dali Sui; Zhongli Jiang; Xiangli Cui; Song Lin
Journal:  J Neurooncol       Date:  2012-12-27       Impact factor: 4.130

10.  Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBM.

Authors:  Forrest W Crawford; Inas S Khayal; Colleen McGue; Suja Saraswathy; Andrea Pirzkall; Soonmee Cha; Kathleen R Lamborn; Susan M Chang; Mitchel S Berger; Sarah J Nelson
Journal:  J Neurooncol       Date:  2008-11-15       Impact factor: 4.130

View more
  14 in total

1.  Advanced MRI may complement histological diagnosis of lower grade gliomas and help in predicting survival.

Authors:  Valeria Cuccarini; A Erbetta; M Farinotti; L Cuppini; F Ghielmetti; B Pollo; F Di Meco; M Grisoli; G Filippini; G Finocchiaro; M G Bruzzone; M Eoli
Journal:  J Neurooncol       Date:  2016-01       Impact factor: 4.130

2.  Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas.

Authors:  Kevin Leu; Garrett A Ott; Albert Lai; Phioanh L Nghiemphu; Whitney B Pope; William H Yong; Linda M Liau; Timothy F Cloughesy; Benjamin M Ellingson
Journal:  J Neurooncol       Date:  2017-05-25       Impact factor: 4.130

3.  Improving the noninvasive classification of glioma genetic subtype with deep learning and diffusion-weighted imaging.

Authors:  Julia Cluceru; Yannet Interian; Joanna J Phillips; Annette M Molinaro; Tracy L Luks; Paula Alcaide-Leon; Marram P Olson; Devika Nair; Marisa LaFontaine; Anny Shai; Pranathi Chunduru; Valentina Pedoia; Javier E Villanueva-Meyer; Susan M Chang; Janine M Lupo
Journal:  Neuro Oncol       Date:  2022-04-01       Impact factor: 13.029

4.  Non-Gaussian diffusion MR imaging of glioma: comparisons of multiple diffusion parameters and correlation with histologic grade and MIB-1 (Ki-67 labeling) index.

Authors:  Ren Yan; Pang Haopeng; Feng Xiaoyuan; Wu Jinsong; Zhang Jiawen; Yao Chengjun; Qiu Tianming; Xiong Ji; Sheng Mao; Ding Yueyue; Zhang Yong; Luo Jianfeng; Yao Zhenwei
Journal:  Neuroradiology       Date:  2015-10-22       Impact factor: 2.804

5.  IVIM perfusion fraction is prognostic for survival in brain glioma.

Authors:  Christian Federau; Milena Cerny; Marion Roux; Pascal J Mosimann; Philippe Maeder; Reto Meuli; Max Wintermark
Journal:  Clin Neuroradiol       Date:  2016-04-26       Impact factor: 3.649

6.  Regional and Volumetric Parameters for Diffusion-Weighted WHO Grade II and III Glioma Genotyping: A Method Comparison.

Authors:  S C Thust; J A Maynard; M Benenati; S J Wastling; L Mancini; Z Jaunmuktane; S Brandner; H R Jäger
Journal:  AJNR Am J Neuroradiol       Date:  2021-01-07       Impact factor: 3.825

7.  Integrative Diffusion-Weighted Imaging and Radiogenomic Network Analysis of Glioblastoma multiforme.

Authors:  Dieter Henrik Heiland; Carl Philipp Simon-Gabriel; Theo Demerath; Gerrit Haaker; Dietmar Pfeifer; Elias Kellner; Valerij G Kiselev; Ori Staszewski; Horst Urbach; Astrid Weyerbrock; Irina Mader
Journal:  Sci Rep       Date:  2017-03-07       Impact factor: 4.379

8.  Apparent diffusion coefficient for molecular subtyping of non-gadolinium-enhancing WHO grade II/III glioma: volumetric segmentation versus two-dimensional region of interest analysis.

Authors:  S C Thust; S Hassanein; S Bisdas; J H Rees; H Hyare; J A Maynard; S Brandner; C Tur; H R Jäger; T A Yousry; L Mancini
Journal:  Eur Radiol       Date:  2018-03-23       Impact factor: 5.315

9.  Diffusion weighted imaging in high-grade gliomas: A histogram-based analysis of apparent diffusion coefficient profile.

Authors:  Georg Gihr; Diana Horvath-Rizea; Elena Hekeler; Oliver Ganslandt; Hans Henkes; Karl-Titus Hoffmann; Cordula Scherlach; Stefan Schob
Journal:  PLoS One       Date:  2021-04-15       Impact factor: 3.240

10.  Histogram Analysis of Diffusion Weighted Imaging in Low-Grade Gliomas: in vivo Characterization of Tumor Architecture and Corresponding Neuropathology.

Authors:  Georg Alexander Gihr; Diana Horvath-Rizea; Elena Hekeler; Oliver Ganslandt; Hans Henkes; Karl-Titus Hoffmann; Cordula Scherlach; Stefan Schob
Journal:  Front Oncol       Date:  2020-02-25       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.